What was the preclinical rationale supporting the ERADICATE trial design?
Trastuzumab deruxtecan was shown to overcome ESR1 mutations in preclinical models
Selective estrogen receptor degraders (SERDs) demonstrated synergistic effects with chemotherapy agents including 5-FU, taxanes, and doxorubicin
Elacestrant was shown to enhance HER2 expression in HER2-low breast cancer cell lines